Clinical and microbiological effects of in vivo miocamycin therapy on oral infections and in surgical prophylaxis.

Periodontal disease is a chronic irregularly progressing condition, posing many therapeutic problems. Difficulties arise particularly when antibiotic therapy is to be added to mechanical and surgical therapy because, in these cases, pharmacotherapy must be long-lasting. For such reasons the antibiotic of choice must have high activity but low toxicity, in order to avoid side-effects. Antibiotic therapy is also used in both marginal and apical acute phlogistic cases, so that the ideal compound should have high diffusion in gingival tissues and alveolar bone. Miocamycin shows all of these features and it can thus be considered the antibiotic of choice in the therapy of acute periodontal infections and in stomatological surgery. In this clinical study the efficacy of miocamycin has been evaluated in 120 cases of acute periodontal phlogosis and in the treatment of advanced periodontal diseases. Patients were microbiologically monitored for the identification of aerobic and anaerobic bacteria all through the study. In acute cases very good results were obtained, both concerning the reduction of pathological signs (94.1% of the cases) and the occurrence of side-effects (10% of the cases). Among the patients who underwent surgical therapy, only 11 out of 80 showed small problems (slight fever and swelling).